We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Rituximab with alkylating agent in anti‐myelin‐associated glycoprotein neuropathy: A retrospective study of 26 cases.
- Authors
Elessa, D.; Grosjean, V.; Lozeron, P.; Harel, S.; Royer, B.; Forgeard, N.; Thèves, F.; Talbot, A.; Malphettes, M.; Bengoufa, D.; Kubis, N.; Arnulf, B.
- Abstract
This article discusses a retrospective study conducted on 26 cases of anti-myelin-associated glycoprotein (anti-MAG) neuropathy, a rare condition characterized by a slowly progressive demyelinating sensory-motor polyneuropathy. The study aimed to evaluate the efficacy of rituximab, a monoclonal antibody, in combination with an alkylating agent in treating this condition. The results showed that treatment with rituximab and an alkylating agent was safe and effective, with 71% of patients showing improvement in their neuropathy symptoms. The study suggests that aggressively targeting the production of anti-MAG antibodies may be crucial in preventing disabling neuropathies. Further research is needed to assess the effectiveness of this treatment approach in larger randomized trials.
- Subjects
ALKYLATING agents; NEUROPATHY; RITUXIMAB; CHRONIC inflammatory demyelinating polyradiculoneuropathy; MUCOSA-associated lymphoid tissue lymphoma; POLYNEUROPATHIES
- Publication
British Journal of Haematology, 2024, Vol 204, Issue 6, p2484
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.19412